tiprankstipranks
Trending News
More News >
Advertisement

EFAV - ETF AI Analysis

Compare

Top Page

EFAV

iShares MSCI EAFE Min Vol Factor ETF (EFAV)

Rating:62Neutral
Price Target:
EFAV’s rating suggests it is a relatively solid, lower-volatility international fund, supported by strong, stable companies like Novartis, DBS Group, and Zurich Insurance, which bring robust profitability, reasonable valuations, and often attractive dividends. Some holdings such as Orange, Swisscom, and Takeda face issues like bearish or weak technical trends, high debt or valuation concerns, and competitive or operational challenges, which likely weigh on the overall rating. The main risk factor is that several top holdings show technical or growth headwinds, meaning the fund could lag if these companies struggle despite their otherwise sound fundamentals.
Positive Factors
Defensive Minimum-Volatility Strategy
The ETF is built to focus on lower-volatility international stocks, which can help smooth out returns during choppy markets.
Broad International Diversification
Holdings spread across many countries, with meaningful exposure to Japan, the UK, Switzerland, and others, reduce reliance on any single market.
Stable, Defensive Sector Mix
Significant weights in financials, health care, consumer defensive, utilities, and communication services tilt the fund toward traditionally steadier sectors.
Negative Factors
Mixed Performance Among Top Holdings
While some leading positions like Novartis and Swisscom have shown strong gains, others such as Zurich Insurance and Ahold Delhaize have been weak, creating uneven contribution to returns.
Concentration in Japan
A large allocation to Japan means the fund’s results are heavily influenced by that single country’s economic and market conditions.
Limited U.S. Exposure
With only a small slice in U.S. stocks, investors who want exposure to the U.S. market would need to pair this ETF with other funds.

EFAV vs. SPDR S&P 500 ETF (SPY)

EFAV Summary

EFAV is an ETF that follows the MSCI EAFE Minimum Volatility Index, which focuses on stocks from developed countries outside the U.S. and Canada, such as Japan, the UK, and Switzerland. It holds many types of companies, including banks, industrial firms, and healthcare businesses. Well-known holdings include Novartis and Shell. Investors might consider EFAV if they want broad international diversification with a goal of smoother ups and downs than a typical stock fund. A key risk is that it still invests in stocks, so its value can rise and fall with global markets.
How much will it cost me?The iShares MSCI EAFE Min Vol Factor ETF (EFAV) has an expense ratio of 0.20%, which means you’ll pay $2 per year for every $1,000 invested. This is lower than the average for actively managed funds because EFAV is passively managed, tracking an index that focuses on minimizing volatility in developed markets outside North America.
What would affect this ETF?The EFAV ETF could benefit from stable economic growth in developed markets outside North America, particularly in sectors like financials, consumer defensive, and healthcare, which are well-represented in its portfolio. However, it may face challenges from rising interest rates, which could impact financial stocks, or geopolitical tensions in Europe and Asia that might affect market stability. Regulatory changes in these regions or shifts in global trade policies could also influence the ETF's performance.

EFAV Top 10 Holdings

EFAV’s story is about steady, low-drama leadership from overseas blue chips. Swiss pharma giant Novartis and Singapore’s DBS Group are doing much of the heavy lifting, with both stocks rising and giving the fund a calm but positive tilt. Defensive names like Swisscom and Orange are also holding their ground, adding ballast rather than fireworks. On the flip side, Zurich Insurance and Ahold Delhaize have been lagging, acting as mild brakes. Overall, the ETF is spread across defensive sectors in developed markets outside North America, with no single stock dominating the show.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Novartis AG1.70%$93.73MCHF234.28B25.89%
80
Outperform
ORANGE SA1.67%$92.18M€45.65B54.31%
65
Neutral
Swisscom AG1.63%$89.74MCHF34.89B34.61%
67
Neutral
Iberdrola1.59%$87.61M€133.59B47.48%
67
Neutral
Takeda Pharmaceutical Co1.49%$82.46M¥8.85T46.21%
66
Neutral
DBS Group Holdings1.49%$82.06MS$163.06B29.18%
78
Outperform
Koninklijke Ahold Delhaize N.V.1.44%$79.19M€33.50B12.07%
62
Neutral
Shell (UK)1.35%$74.52M£164.82B9.90%
73
Outperform
Unilever1.34%$73.92M£116.01B5.48%
72
Outperform
Zurich Insurance Group1.34%$73.88MCHF78.06B14.34%
78
Outperform

EFAV Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
87.35
Positive
100DMA
85.60
Positive
200DMA
83.94
Positive
Market Momentum
MACD
1.56
Negative
RSI
80.59
Negative
STOCH
96.01
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For EFAV, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 89.44, equal to the 50-day MA of 87.35, and equal to the 200-day MA of 83.94, indicating a bullish trend. The MACD of 1.56 indicates Negative momentum. The RSI at 80.59 is Negative, neither overbought nor oversold. The STOCH value of 96.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EFAV.

EFAV Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$5.50B0.20%
$8.66B0.35%
$7.78B0.28%
$6.42B0.07%
$2.34B0.58%
$1.37B0.20%
Performance Comparison
Ticker
Company Name
Price
Change
% Change
EFAV
iShares MSCI EAFE Min Vol Factor ETF
93.60
21.53
29.87%
DBEF
Xtrackers MSCI EAFE Hedged Equity ETF
FENI
Fidelity Enhanced International ETF
BBIN
JPMorgan BetaBuilders International Equity ETF
IHDG
WisdomTree International Hedged Quality Dividend Growth Fund
HFXI
IQ 50 Percent Hedged FTSE International ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement